NASDAQ:CRBP Corbus Pharmaceuticals Q2 2025 Earnings Report $9.26 -0.01 (-0.11%) Closing price 04:00 PM EasternExtended Trading$9.50 +0.24 (+2.59%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Corbus Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$1.35Beat/MissN/AOne Year Ago EPSN/ACorbus Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACorbus Pharmaceuticals Announcement DetailsQuarterQ2 2025Date8/5/2025TimeBefore Market OpensConference Call DateTuesday, August 5, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Corbus Pharmaceuticals Earnings HeadlinesCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is largely controlled by institutional shareholders who own 51% of the companyJuly 20, 2025 | finance.yahoo.comCorbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors despite daily gainsJuly 15, 2025 | marketwatch.comNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system tracks breaking AI news and shows when to trade.📈 AI-backed. Beginner-friendly. Results proven.July 30 at 2:00 AM | Timothy Sykes (Ad)Corbus Pharmaceuticals Reports No Neuropsychiatric Events in Phase 1 SAD Study of CRB-913, Advancing to MAD Portion - NasdaqJuly 2, 2025 | nasdaq.comCorbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with PembrolizumabJune 25, 2025 | globenewswire.comCorbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity SymposiumJune 24, 2025 | globenewswire.comSee More Corbus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Corbus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corbus Pharmaceuticals and other key companies, straight to your email. Email Address About Corbus PharmaceuticalsCorbus Pharmaceuticals (NASDAQ:CRBP), a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.View Corbus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead?Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag?Deckers Stock Recovers on Strong Earnings—More Upside Ahead?3 Reasons Tesla's Post-Earnings Hangover Looks Like a BuyCan Qualcomm Shock Wall Street With Its Q3 Earnings?T-Mobile Earnings Show You Why This Is a Stock to HoldAmerican Airlines Earnings Miss, But Bulls Aren’t Backing Off Upcoming Earnings Apple (7/31/2025)Amazon.com (7/31/2025)Comcast (7/31/2025)Coinbase Global (7/31/2025)KLA (7/31/2025)MicroStrategy (7/31/2025)Sanofi (7/31/2025)AbbVie (7/31/2025)Arthur J. Gallagher & Co. (7/31/2025)Air Products and Chemicals (7/31/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
